This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Scynexis, Inc.. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Stephen Andrew Barat: Innovator in Antifungal Treatments
Introduction
Stephen Andrew Barat is an inventor based in Mendham, NJ (US). He is currently associated with Scynexis, Inc., where he focuses on developing innovative antifungal treatments. Despite having no granted patents to his name, his contributions to the field of medicine are noteworthy.
Latest Patent Applications
Stephen's latest patent applications include significant advancements in antifungal therapies. One of his applications is titled "Triterpenoid Antifungals for the Treatment or Prevention of Pneumocystis Spp. Pneumonia." This application discusses enfumafungin derivative triterpenoid antifungal compounds that are effective in treating and preventing pneumonia caused by Pneumocystis species. These compounds demonstrate unexpected efficacy, including the ability to reduce the lung burden of cyst and trophic forms of the fungi. They are inhibitors of (1,3)-β-D-glucan synthesis, showcasing potent activity in in vivo models and adequate tissue penetration into the lungs.
Another application is "Antifungal Agents for Candida Auris Decolonization." This application focuses on enfumafungin derivative triterpenoid antifungal compounds used to decolonize fungi from anatomical areas of subjects colonized by fungi. The compounds can effectively decolonize from body sites such as skin and mucosa, benefiting individuals who have previously suffered from infections and are at risk of relapse or transmission.
Conclusion
Stephen Andrew Barat is making significant strides in the field of antifungal treatments through his innovative research and patent applications. His work at Scynexis, Inc. highlights the importance of developing effective therapies for fungal infections.